Acasti Pharma Inc.

2.09-0.0300-1.42%Vol 225.01K1Y Perf 24.17%
Sep 23rd, 2021 14:33 DELAYED
BID2.08 ASK2.09
Open2.12 Previous Close2.12
Pre-Market2.12 After-Market-
 - -%  - -
Target Price
0.15 
Analyst Rating
Moderate Buy 1.75
Potential %
-92.79 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★★     57.08
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
+ —    -
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
8.58 
Earnings Rating
Buy
Market Cap54.44M 
Earnings Date
15th Nov 2021
Alpha0.01 Standard Deviation0.36
Beta1.87 

Today's Price Range

2.062.14

52W Range

1.379.76

5 Year PE Ratio Range

-2.90-3.00

Summary:

Neutral

Technical Indicators: Sell
Moving Averages: Strong Buy
Performance
1 Week
-2.30%
1 Month
380.73%
3 Months
255.47%
6 Months
220.48%
1 Year
24.17%
3 Years
259.32%
5 Years
12.17%
10 Years
-85.96%

TickerPriceChg.Chg.%
ACST2.09-0.0300-1.42
AAPL146.891.04000.71
GOOG2 843.0324.26000.86
MSFT299.991.41000.47
XOM57.212.00003.62
WFC47.960.88001.87
JNJ165.431.50000.92
FB347.123.91001.14
GE103.575.03005.10
JPM161.455.54003.55
Financial StrengthValueIndustryS&P 500US Markets
24.80
25.80
0.00
0.00
45.50
Leverage Ratio 1.20
ProfitabilityValueIndustryS&P 500US Markets
60.80
-9 541.80
-9 350.00
-
-
RevenueValueIndustryS&P 500US Markets
192.36K
0.00
-
-
Earnings HistoryEstimateReportedSurprise %
Q01 2022--0.01-
Q04 2021--0.03-
Q03 2021--0.02-
Q02 2021-0.07-0.0528.57
Q01 2021-0.07-0.0528.57
Q04 2020-0.09-0.0544.44
Q03 2020-0.13-0.14-7.69
Q02 2020-0.08-0.080.00
Earnings Per EndEstimateRevision %Trend
12/2020 QR-0.07-16.67Negative
3/2021 QR0.00100.00Positive
3/2021 FY-0.195.00Positive
3/2022 FY-0.180.00-
Next Report Date15th Nov 2021
Estimated EPS Next Report-
Estimates Count-
EPS Growth Next 5 Years %-
Volume Overview
Volume225.01K
Shares Outstanding26.05M
Shares Float44.26M
Trades Count1.34K
Dollar Volume12.48M
Avg. Volume2.69M
Avg. Weekly Volume409.65K
Avg. Monthly Volume1.16M
Avg. Quarterly Volume1.02M

Acasti Pharma Inc. (NASDAQ: ACST) stock closed at 2.12 per share at the end of the most recent trading day (a 0.47% change compared to the prior day closing price) with a volume of 266.50K shares and market capitalization of 54.44M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 32 people. Acasti Pharma Inc. CEO is Janelle D'Alvise.

The one-year performance of Acasti Pharma Inc. stock is 24.17%, while year-to-date (YTD) performance is 552.31%. ACST stock has a five-year performance of 12.17%. Its 52-week range is between 1.37 and 9.76, which gives ACST stock a 52-week price range ratio of 8.58%

Acasti Pharma Inc. currently has a PE ratio of -2.30, a price-to-book (PB) ratio of 1.82, a price-to-sale (PS) ratio of 467.39, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -44.38%, a ROC of -56.78% and a ROE of -55.70%. The company’s profit margin is -%, its EBITDA margin is -9 350.00%, and its revenue ttm is $192.36 Thousand , which makes it $0.00 revenue per share.

Of the last four earnings reports from Acasti Pharma Inc., there were 1 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $0.00 for the next earnings report. Acasti Pharma Inc.’s next earnings report date is 15th Nov 2021.

The consensus rating of Wall Street analysts for Acasti Pharma Inc. is Moderate Buy (1.75), with a target price of $0.15, which is -92.79% compared to the current price. The earnings rating for Acasti Pharma Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Acasti Pharma Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Acasti Pharma Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 27.23, ATR14 : 0.17, CCI20 : 21.97, Chaikin Money Flow : -0.25, MACD : 0.35, Money Flow Index : 34.73, ROC : -10.92, RSI : 64.50, STOCH (14,3) : 20.29, STOCH RSI : 0.27, UO : 41.86, Williams %R : -79.71), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Acasti Pharma Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (50.00 %)
3 (60.00 %)
2 (50.00 %)
Moderate Buy
1 (25.00 %)
1 (20.00 %)
1 (25.00 %)
Hold
1 (25.00 %)
1 (20.00 %)
1 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingModerate Buy
1.75
Moderate Buy
1.60
Moderate Buy
1.75

Acasti Pharma Inc.

Acasti Pharma Inc is a biopharmaceutical innovator advancing a cardiovascular drug, CaPre (omega-3 phospholipid), for the treatment of hypertriglyceridemia, a chronic condition affecting an estimated one third of the U.S. population. The company is focused on addressing a critical market need for an effective, safe and well-absorbing omega-3 therapeutic that can make a positive impact on the blood lipids associated with cardiovascular disease risk. The Company is developing CaPre in a Phase 3 clinical program in patients with severe hypertriglyceridemia.

CEO: Janelle D'Alvise

Telephone: +1 438 399-7114

Address: 545, Promenade du Centropolis, Laval H7T 0A3, QC, CA

Number of employees: 32

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

59%41%

Bearish Bullish

59%41%

Bearish Bullish

59%41%

TipRanks News for ACST

Mon, 13 Sep 2021 18:31 GMT Acasti Pharma: Low Chance of a Rebound

- TipRanks. All rights reserved.

News

Stocktwits